Pancreatic cancer
Conditions
Sponsors
Liaoning Cancer Hospital & Institute
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: ? Patients aged = 18 years and = 75 years old; ? The patient was diagnosed as pancreatic cancer by histology/cytology; ? Meeting one of the following conditions: a) Patients who are judged to be resectable/ borderline resectable pancreatic cancer according to the "resectable standard of pancreatic cancer" in the pancreatic cancer diagnosis and treatment guidelines (2022 version) and are to receive new adjuvant treatment; b) According to the "resectability criteria of pancreatic cancer" in the pancreatic cancer diagnosis and treatment guidelines (2022 version), the patients who are judged as unresectable pancreatic cancer and are to receive transformation treatment; c) Patients who have undergone curative resection and plan to receive postoperative adjuvant treatment; d) Patients who are clinically determined not to undergo surgery and plan for systematic systemic treatment; ? Before treatment, sufficient and fresh tissue samples can be obtained for organoid establishment through various biopsy methods; ? Patients with ECOG physical fitness score of 0 or 1; ? Expected survival time = 12 weeks; ? The patient voluntarily joined this study and signed an informed consent form (ICF), with good compliance and cooperation in follow-up.
Exclusion criteria
Exclusion criteria: ? Pregnant and lactating women; ? Patients who have clinically significant (i.e. active) heart disease (such as congestive heart failure, symptomatic coronary artery disease, arrhythmia, etc.) or myocardial infarction within the past 12 months; ? Patients with other malignant tumors within 5 years, excluding cured skin cancer; ? Any uncontrolled active bacterial, viral, fungal, mycobacterial, parasitic or other infections (excluding nail bed skin fungal infections) or any major systemic infection events requiring intravenous antibiotic treatment or hospitalization within 4 weeks prior to enrollment (excluding tumor fever); ? The researchers believe that patients are not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diseases free survival;Objective response rate;R0 resection rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival;Overall survival;Pathologic complete response; | — |
Countries
China
Contacts
Public ContactLiu Yefu
Liaoning Cancer Hospital & Institute
Outcome results
None listed